A Novel Application of Furazolidone: Anti-Leukemic Activity in Acute Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Jiang, Xueqing ^a,b   Sun, Lin ^a,b   Qiu, Jihui Julia ^b,c   Sun, Xiujing ^b   Li, Sen ^b   Wang, Xiyin ^b   So, Chi Wai Eric ^d   Dong, Shuo ^b  

^a CENTRAL HOSPITAL OF WUHAN   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; ETO PROTEIN; FURAZOLIDONE; HYBRID PROTEIN; LEUKEMIA FUSION PROTEIN; NATURAL PRODUCT; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; BONE MARROW; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MARKETING; DRUG SCREENING; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; HELICOBACTER INFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALIGNANT TRANSFORMATION; PATENT; PEPTIC ULCER; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTOZOAL INFECTION; VIRAL GENE DELIVERY SYSTEM; VIRUS TRANSFORMATION;

EID: 84881238340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072335     Document Type: Article

References (26)

1. Stone RM, O'Donnell MR, Sekeres MA (2004) Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program: 98-117.
2. Estey E, Dohner H, (2006) Acute myeloid leukaemia. Lancet 368: 1894-1907.
3. Burnett AK, (2012) Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program 2012: 1-6.
4. de The H, Chen Z, (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10: 775-783.
5. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, et al. (2007) Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 12: 36-51.
6. Qiu JJ, Lu X, Zeisig BB, Ma Z, Cai X, et al. (2010) Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}. Blood 115: 643-652.
7. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, et al. (2010) beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18: 606-618.
8. Kwok C, Zeisig BB, Qiu J, Dong S, So CW, (2009) Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A 106: 2853-2858.
9. Ali BH, (1999) Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun 23: 343-360.
10. Zullo A, Ierardi E, Hassan C, De Francesco V, (2012) Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol 18: 11-17.
11. Zheng ZT, Wang YB, (1992) Treatment of peptic ulcer disease with furazolidone. J Gastroenterol Hepatol 7: 533-537.
12. Smith LL, Yeung J, Zeisig BB, Popov N, Huijbers I, et al. (2011) Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 8: 649-662.
13. Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner P, et al. (2009) Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication. BMC Gastroenterol 9: 38.
14. Jin X, Tang S, Chen Q, Zou J, Zhang T, et al. (2011) Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells. Toxicol Lett 201: 205-212.
15. Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, et al. (2011) Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol 48: 261-264.
16. Meyer M, Rubsamen D, Slany R, Illmer T, Stabla K, et al. (2009) Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 4: e7768.
17. Chylicki K, Ehinger M, Svedberg H, Bergh G, Olsson I, et al. (2000) p53-mediated differentiation of the erythroleukemia cell line K562. Cell Growth Differ 11: 315-324.
18. Ehinger M, Bergh G, Johnsson E, Gullberg U, Olsson I, (1997) The tumor suppressor gene p53 can mediate transforming growth [corrected] factor beta1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein. Cell Growth Differ 8: 1127-1137.
19. Tenen DG, (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89-101.
20. Licht JD, (2001) AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20: 5660-5679.
21. Lam K, Zhang DE, (2012) RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci 17: 1120-1139.
22. Evaluation of certain veterinary drug residues in food. Fortieth report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organ Tech Rep Ser 832: 1-62.
23. Rabbani GH, Butler T, Shahrier M, Mazumdar R, Islam MR, (1991) Efficacy of a single dose of furazolidone for treatment of cholera in children. Antimicrob Agents Chemother 35: 1864-1867.
24. Treiber G, Ammon S, Malfertheiner P, Klotz U, (2002) Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 7: 225-231.
25. Dong S, Zhu J, Reid A, Strutt P, Guidez F, et al. (1996) Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger- retinoic acid receptor-alpha fusion protein. Proc Natl Acad Sci U S A 93: 3624-3629.
26. Qiu JJ, Chu H, Lu X, Jiang X, Dong S, (2011) The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia. Oncogene 30: 967-977.